Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of TNF (tumour necrosis factor)-Blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis

Next Previous
X
Search
Trial Profile

Use of TNF (tumour necrosis factor)-Blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Hydroxychloroquine; Methotrexate; Prednisolone; Prednisone; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms NEORACo

    • Most Recent Events

    • 01 May 2022 Results evaluating whether pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab published in the Scandinavian Journal of Rheumatology
    • 15 Nov 2019 Ten year results of NEORACo trial published in The Journal of Rheumatology
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top